Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- Trade Name: Ukoniq (TG Therapeutics)
- Indications:
Relapsed or refractory marginal zone lymphoma (subsequent to an anti-CD20-based regimen)
Relapsed or refractory follicular lymphoma (following previous systemic therap
- Class: Kinase inhibitor, Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
- Half-life: 91 hours
- FDA Approval Date: 02/05/2021
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: May cause fetal harm when administered to a pregnant woman. Advise use of contraceptives.
- See adverse reactions attributed to class:
Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
